Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

Remember to use the “Streck Tube”, the most trusted preanalytical solution for cell free DNA

Products are for professional/laboratory use only.

For all liquid biopsies, remember to use the “Streck Tube”, the No.1 tube worldwide for stabilisation of cell free DNA.

Cell-Free DNA BCT is a blood collection tube with a preservative stabilising nucleated blood cells and preventing the release of gDNA, allowing isolation of high-quality cell-free DNA.

Abacus dx distributes Streck products in Australia only.

Benefits of the “Streck Tube” include:

  • High quality cell-free DNA recovery for reduced variability associated with cell-free DNA sample preparation
  • Reduced need for immediate plasma preparation and CTC processing
  • Multiple applications – suitable for use in clinical research studies, drug discovery and diagnostic assay development
  • Confidence in stability and a trusted solution– with over 17 million tubes shipped worldwide
  • No need to centrifuge immediately after collection

From blood collection to analysis, Streck cell free DNA tubes allow for ease of workflow to produce high quality DNA for analysis.


View Streck Cell-Free DNA BCT Flyer

Download Now >

Want to know more about Streck Cell-Free DNA BCT?

Contact Us Now >



Request a Quote

Request Quote

Recent Posts

Invivoscribe – NPM1 MRD Assay now available globally

Invivoscribe’s NPM1 MRD Assay is an NGS-based, targeted, deep-sequencing assay that detects and monitors DNA sequences specific to identified mutations from the primary sample identified at diagnosis with an allelic sensitivity…

Read full article

ZytoVision – New ZytoLight Probes

NECTIN4  |  MALT1/IGH  |  TNFRSF14/1q25  |  PLAG1 (more…)

Read full article

ImmunoIVD – Spot-it™ Newborn Screening Assays

ImmunoIVD, Early Detection for Life-Saving interventions Brisbane, Australia – July 31, 2025 (more…)

Read full article